First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor

Autor: Hidetoshi Shimizu, Michael A. Tortorici, Yoshiyasu Ohta, Kei Ogawa, Sheikh Mohammed Ashfaq Rahman, Aya Fujii, Yuki Hiraga, Mizue Kawai, Kanami Sugimoto‐Kawabata, Mattheus (Thijs) vanIersel, Jan Jaap vanLier, Stephen Djedjos, B. T. Slingsby, David M. Rodman

Publikováno v: Clinical and Translational Science, Vol 17, Iss 8, Pp n/a-n/a (2024)

Abstract Dysregulation of the mineralocorticoid hormone aldosterone is an increasingly prevalent cause of hypertension. Aldosterone synthase (CYP11B2) shares 93% homology to 11β‐hydroxylase (CYP11B1), which produces cortisol. Lorundrostat, a highl

Externí odkaz: https://doaj.org/article/c92800d2ef6c453baa9149dda089faef

First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor.

Autor: Shimizu, Hidetoshi¹ (AUTHOR), Tortorici, Michael A.² (AUTHOR) mtortorici@mineralystx.com, Ohta, Yoshiyasu³ (AUTHOR), Ogawa, Kei¹ (AUTHOR), Rahman, Sheikh Mohammed Ashfaq⁴ (AUTHOR), Fujii, Aya⁵ (AUTHOR), Hiraga, Yuki⁶ (AUTHOR), Kawai, Mizue⁷ (AUTHOR), Sugimoto‐Kawabata, Kanami⁸ (AUTHOR), van Iersel, Mattheus⁹ (AUTHOR), van Lier, Jan Jaap⁹ (AUTHOR), Djedjos, Stephen² (AUTHOR), Slingsby, B. T.² (AUTHOR), Rodman, David M.² (AUTHOR)

Publikováno v: CTS: Clinical & Translational Science. Aug2024, Vol. 17 Issue 8, p1-13. 13p.

Clinical Pharmacology Group Researchers Reveal New Findings on Hypertension (First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor).

Publikováno v: Cardiovascular Week; 9/16/2024, p154-154, 1p